Seven problems for Geron
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
BeiGene has a strong presence at this year’s AACR, which features several notable duels.